A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Nature

Volumn 434, Issue 7037, 2005, Pages 1144-1148

  James, Chloé ^a   Ugo, Valérie ^a,b,c   Le Couédic, Jean Pierre ^a   Staerk, Judith ^d   Delhommeau, François ^a,c   Lacout, Catherine ^a   Garçon, Loïc ^a   Raslova, Hana ^a   Berger, Roland ^e   Bennaceur Griscelli, Annelise ^a,f   Villeval, Jean Luc ^a   Constantinescu, Stefan N ^d   Casadevall, Nicole ^a,c   Vainchenker, William ^a,g  

^a INSERM   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d DE DUVE INSTITUTE   (Belgium)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELLS; CLONING; ENZYMES; GENES; MOLECULAR BIOLOGY;

CYTOKINES; JANUS KINASE 2 (JK2); MUTATION; MYELOPROLIFERATIVE DISORDERS;

DISEASES;

CYTOKINE; ERYTHROPOIETIN; PROTEIN TYROSINE KINASE; INTERLEUKIN 3; JAK2 PROTEIN, HUMAN; JAK2 PROTEIN, MOUSE; JANUS KINASE 2; ONCOPROTEIN; SMALL INTERFERING RNA;

MEDICINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLONAL VARIATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG SENSITIVITY; ENZYME ACTIVITY; ERYTHROCYTOSIS; GENE; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYPERSENSITIVITY; JAK2 GENE; JH2 PSEUDOKINASE DOMAIN; LEUKOCYTOSIS; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPLENOMEGALY; THROMBOSIS; ANIMAL; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECT; EXON; GENETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ANIMALIA; JANUS;

ANIMALS; BASE SEQUENCE; BONE MARROW TRANSPLANTATION; CELL LINE, TUMOR; CELL PROLIFERATION; ERYTHROPOIETIN; EXONS; HUMANS; INTERLEUKIN-3; JANUS KINASE 2; MICE; MUTATION; POLYCYTHEMIA; POLYCYTHEMIA VERA; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 17844383458     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03546     Document Type: Article

References (27)

1. Spivak, J. L. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin. Hematol. 41 (2 suppl. 3), 1-5 (2004).
2. Prchal, J. T. Polycythemia vera and other primary polycythemias. Curr. Opin. Hematol. 12, 112-116 (2005).
3. Spivak, J. L. Polycythemia vera: myths, mechanisms, and management. Blood 100, 4272-4290 (2002).
4. Prchal, J. F. & Axelrad, A. A. Bone-marrow responses in polycythemia vera. N. Engl. J. Med. 290, 1382 (1974).
5. Casadevall, N. et al. Erythroid progenitors in polycythemia vera. Demonstration of their hypersensitivity to erythropoietin using serum-free cultures. Blood 59, 447-451 (1982).
6. Ugo, V. et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycylhemia vera. Exp. Hematol. 32, 179-187 (2004).
7. Witthuhn, B. A. et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74, 227-236 (1993).
8. Bernabei, P. et al. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J. Leukoc. Biol. 70, 950-960 (2001).
9. Kralovics, R., Guan, Y. & Prchal, J. T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp. Hematol. 30, 229-236 (2002).
10. Najfeld, V., Montella, L., Scalise, A. & Fruchtman, S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br. J. Haematol. 119, 558-566 (2002).
11. Kralovics, R., Stockton, D. W. & Prchal, J. T. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 102, 3793-3796 (2003).
12. Saharinen, P., Takaluoma, K. & Silvennoinen, O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20, 3387-3395 (2000).
13. Saharinen, P., Vihinen, M. & Silvennoinen, O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell 14, 1448-1459 (2003).
14. Lindauer, K., Loerting, T., Liedt, K. R. & Kroemer, R. T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 14, 27-37 (2001).
15. Argetsinger, L. S. et al. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 24, 4955-4967 (2004).
16. Feener, E. P., Rosario, F., Dunn, S. L., Stancheva, Z. & Myers, M. G. J. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol. Cell. Biol. 24, 4968-4978 (2004).
17. Luo, H. et al. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol. Cell. Biol. 17, 1562-1571 (1997).
18. Kohlhuber, F. et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol. Cell. Biol. 17, 695-706 (1997).
19. Lacronique, V. et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312 (1997).
20. Huang, L. J., Constantinescu, S. N. & Lodish, H. P. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol. Cell 8, 1327-1338 (2001).
21. Zhao, S. et al. JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells. EMBO J. 21, 2159-2167 (2002).
22. Pearson, T. C. & Messinezy, M. The diagnostic criteria of polycythaemia rubra vera. Leuk. Lymphoma 22 (suppl. 1), 87-93 (1996).
23. Cools, J. et al. Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia. Cytogenet. Cell Genet. 85, 260-266 (1999).
24. Le Coniat, M., Romana, S. P. & Berger, R. Partial chromosome 21 amplification in a child with acute lymphoblastic leukemia. Genes Chromosom. Cancer 14, 204-209 (1995).
25. Dumoutier, L., Van Roost, E., Colau, D. & Renauld, J. C. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc. Natl Acad. Sci. USA 97, 10144-10149 (2000).
26. Chagraoui, H. et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood 101, 2983-2989 (2003).
27. Dorsch, M. et al. Ectopic expression of delta4 impairs hematopoietic developement and leads to lymphoproliferative disease. Blood 100, 2046-2055 (2002).